ArticleBMC cancer2025
Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundCell-free circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) has demonstrated the potential to guide the personalized treatment of non-small cell lung cancer (NSCLC). Furthermore, clinical treatment-response data guided by ctDNA remain scarce. This study systematically evaluates an NGS platform’s detection accuracy and clinical utility in a large Chinese NSCLC cohort, establishing therapeutic-response evidence.
methodsWe first established the cutoff and quality control parameters for the NGS test using clinical plasma samples from NSCLC patients, with ddPCR serving as the reference standard. The performance of the assay was then robustly validated in an independent cohort of 522 samples. Finally, we analyzed the driver and resistance mutations for their distribution, concordance with tissue samples, and therapeutic relevance.
resultsThrough analysis of plasma samples using ROC and downsample methods, we established a 0.2% detection threshold and identified > 1400x mean effective depth as the critical QC metric; under these parameters, ddPCR validation of 17 specific sites in the 522-sample cohort demonstrated > 80% positive percentage agreement (PPA) and > 95% negative percentage agreement (NPA), confirming strong NGS-ddPCR concordance. The 21-gene panel detected mutations in 73.75% of patients, with 45.59% harboring NCCN-recommended targetable mutations. In the tissue-plasma concordance analysis, stage-specific performance was observed: Stage III showed 28.57% PPA (2/7) versus 99.20% NPA (124/125), while Stage IV demonstrated 99.20% PPA (124/125) and 99.46% NPA (183/184). Clinically relevant plasma-specific mutations were identified throughout, and pooled data demonstrated equivalent targeted therapy response rates between this ctDNA-based NGS and National Medical Products Administration (NMPA)-approved tissue-based assays.
conclusionsThis study highlights the feasibility of ctDNA-based NGS in clinical practice, offering valuable and clinically relevant mutational genomic profiling for stage III/IV NSCLC in Chinese patients.
trial registrationThis study is registered with Chinese Clinical Trial Registry, ChiCTR2000041034, on December 16, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.